FDA-approved product exists

Tirzepatide

Also called Zepbound, Mounjaro.

Tirzepatide has FDA-approved products for specific uses. This page cites 2 sources, and the strongest evidence comes from human trials.

Status: FDA-approved product exists
Form: Pen injection
Half-life: about 5 days, FDA label
Strongest evidence: Human trials
Cited claims: 2
Last updated: November 6, 2026

What the evidence says

Each claim names the kind of study behind it, what it can't tell you, and where it comes from.

Human trials
Tirzepatide supports weight loss in adults with obesity.
Limits: Controlled trials studied specific prescription products alongside lifestyle changes. Results vary and do not establish the safety or effectiveness of other preparations.
- Jastreboff et al., 2022: Tirzepatide Once Weekly for the Treatment of Obesity
Human trials
Tirzepatide has an elimination half-life of about five days.
Limits: Population estimate, not a measurement of your blood level. The chart uses assumed absorption of 0.12/hour to approximate the time to peak; the label does not supply that rate.
- FDA label: Zepbound, clinical pharmacology

Regulatory status

United States

FDA-approved products exist for specific indications; approval applies to the product, not every preparation.

FDA label: Zepbound, clinical pharmacology

Half-life

The FDA label lists a half-life of about 5 days. Here is what that looks like for a weekly schedule, as Peptiday draws it. It's a population estimate, not a measurement of your blood level.

Illustration relative to the modeled peak. The half-life comes from the label and absorption is assumed. It isn't a blood measurement, so don't use it to choose amounts or timing.